Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.81 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.81 |
| ▸ | FYN | P06241 | 1/20 | 0.77 |
| ▸ | SRC | P12931 | 1/20 | 0.77 |
| ▸ | BLK | P51451 | 1/20 | 0.77 |
| ▸ | BMX | P51813 | 1/20 | 0.77 |
| ▸ | JAK3 | P52333 | 1/20 | 0.77 |
| ▸ | BTK | Q06187 | 1/20 | 0.77 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583800 | 1.00 | EGFR (0.81) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL6586413 | 0.90 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL1417862 | 0.90 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL1417861 | 0.90 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2988658 | 0.90 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2988661 | 0.90 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL2986126 | 0.89 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL1418066 | 0.88 | EGFR (0.81) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL7213752 | 0.88 | EGFR (0.89) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL1418064 | 0.88 | EGFR (0.81) | EGFRERBB2FYNSRCBLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000039-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | WYETH CORP (US) | 2004-06-09 | — | — | EP | claimed |
| US-6251912-B1 | Substituted quinazoline derivatives | AMERICAN CYANAMID COMPANY | 2001-06-26 | — | — | US | claimed |
| EP-1000039-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | American Cyanamid Company (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999009016-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | KUMQUAT BIOSCIENCES INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2021035096-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | KUMQUAT BIOSCIENCES INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| EP-1000039-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | WYETH CORP (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6251912-B1 | Substituted quinazoline derivatives | AMERICAN CYANAMID COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-1000039-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | American Cyanamid Company (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999009016-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | CD2BP2, CD47, CD74 | EGFR 1892/4885ERBB2 2230/4885FYN 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.